Search Results
Jul 15, 2026, 06:00 ET Kelun-Biotech and Harbour BioMed Announce NMPA Approval of IND Application for SKB575/HBM7575 for the Treatment of Asthma
in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please
More news about: Kelun-Biotech
Jul 14, 2026, 20:00 ET 全球首個ADC+IO對比免疫聯合化療一線治療PD-L1陰性非鱗狀NSCLC III期研究達到主要終點，蘆康沙妥珠單抗聯合帕博利珠單抗有望重塑治療格局
NSCLC患者，免疫聯合化療作為一線標準治療雖在一定程度上改善了患者預後，但其長期生存獲益仍然有限。此次OptiTROP-Lung06 III期已達到主要終點，是PD-L1陰性NSCLC一線治療領域的一項重要突破，該研究不僅為蘆康沙妥珠單抗(sac-TMT)聯合帕博利珠單抗這一『ADC+IO』方案提供了堅實的循證醫學證據，更有望為這類患者帶來超越當前標準治療的全新一線選擇，實現更優的生存獲益。」科倫博泰首席執行官葛均友博士表示：「很高興看到蘆康沙妥珠單抗(sac-TM
More news about: 科倫博泰
Jul 14, 2026, 19:30 ET Kelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Met Primary Endpoint
in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please
More news about: Kelun-Biotech
Jul 14, 2026, 04:18 ET Phase II Trial of Cadonilimab(PD-1/CTLA-4) Combination Regimen Launches in the United States for Perioperative Treatment of Gastric Cancer
comprehensive R&D innovation ecosystem anchored by its proprietary Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.Backed
More news about: Akeso, Inc.
Jul 13, 2026, 10:31 ET Metastatic Castration-resistant Prostate Cancer Market Poised for Strong Growth by 2036, Due to the Launch of Drug Classes Such as Anti-B7-H3 ADC, PROTAC Protein Degrader, NTD AR Inhibitor, Radionuclide Therapy, and Several Others | DelveInsight
Prostate Cancer Clinical TrialsSadaf Javed, Functional Head of Forecasting at DelveInsight, said that the emergence of Anti-B7-H3 ADC (MGC018), PROTAC protein degrader (ARV-766), First-in-Class NTD AR Inhibitor (EPI-7386), radionuclide therapy, and PSMA-Targeted therapy (177Lu-DOTA-rosopatamab,
More news about: DelveInsight Business Research, LLP
Jul 13, 2026, 04:56 ET Leads Biolabs Announces Multiple Studies Selected for ESMO 2026, Highlighting the Growing Global Competitiveness of Its Core Pipeline
multiple proprietary technology platforms, including LeadsBody (a CD3 T-cell engager platform), X-body (a 4-1BB engager platform), TOPiKinectics (an ADC platform) and ImBiTDC (a TDC platform), which serve as the cornerstone for its continued innovation and have been validated by the clinical outcomes
More news about: Leads Biolabs
Jul 13, 2026, 00:00 ET Antengene Announces Receipt of USD 60 Million Upfront Payment from UCB
preclinical to commercial stages, with key investigational candidates including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 x 4-1BB bispecific antibody), ATG-125 (B7-H3 × PD-L1 bispecific ADC), ATG-207 (αCD3-TGF-β bifunctional fusion protein), as well as T cell engager (TCE) programs
More news about: Antengene Corporation Limited
Jul 10, 2026, 04:53 ET Priority Review Granted to PD-L1/4-1BB Bispecific Antibody Opamtistomig, Accelerating Commercialization and Addressing Unmet Need in EP-NEC
multiple proprietary technology platforms, including LeadsBody (a CD3 T-cell engager platform), X-body (a 4-1BB engager platform), TOPiKinectics (an ADC platform) and ImBiTDC (a TDC platform), which serve as the cornerstone for its continued innovation and have been validated by the clinical outcomes
More news about: Nanjing Leads Biolabs Co., Ltd.
Jul 09, 2026, 16:15 ET /C O R R E C T I O N -- RyboDyn/
advance preclinical development of two novel antibody-based therapies for lung cancer. The award will support the company's antibody-drug conjugate (ADC) and T-cell engager (TCE) programs targeting two previously undiscovered cell-surface proteins identified directly from patient tumors through CypherAtlas™,
More news about: RyboDyn
Jul 08, 2026, 10:17 ET Tsingke Highlights AI-Driven CLDN18.2 Antibody Discovery at AIS 2026
developability, highlighting the potential of integrating AI with experimental validation to accelerate therapeutic antibody and antibody-drug conjugate (ADC) development.End-to-End Antibody Development CapabilitiesIn addition to its scientific presentation, Tsingke showcased
More news about: Beijing Tsingke Biotech Co., Ltd.
Jul 08, 2026, 10:17 ET Tsingke Highlights AI-Driven CLDN18.2 Antibody Discovery at AIS 2026
developability, highlighting the potential of integrating AI with experimental validation to accelerate therapeutic antibody and antibody-drug conjugate (ADC) development.End-to-End Antibody Development CapabilitiesIn addition to its scientific presentation, Tsingke showcased its integrated
More news about: Beijing Tsingke Biotech Co., Ltd.
Jul 08, 2026, 10:00 ET Altruist Biologics' Hangzhou Antibody-Drug Conjugate Facility Receives Provincial Regulatory Approval for Segmented Production
and operational control.The company has successfully managed over 40 ADC and AXC projects, and has developed ADC molecules spanning from pre-IND to phase three and PPQ. For more information about Altruist Biologics' ADC and bioconjugate capabilities, please visit:
More news about: Altruist Biologics
Jul 08, 2026, 10:00 ET Altruist Biologics' Hangzhou Antibody-Drug Conjugate Facility Receives Provincial Regulatory Approval for Segmented Production
and operational control.The company has successfully managed over 40 ADC and AXC projects, and has developed ADC molecules spanning from pre-IND to phase three and PPQ. For more information about Altruist Biologics' ADC and bioconjugate capabilities, please visit:
More news about: Altruist Biologics
Jul 01, 2026, 16:05 ET ADC Therapeutics Announces New Employee Inducement Grant
Company.About ADC TherapeuticsADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA® (loncastuximab tesirine-lpyl).ADC Therapeutics'
More news about: ADC Therapeutics SA
Jun 30, 2026, 07:15 ET ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial
therapy.About ADC TherapeuticsADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl).ADC Therapeutics'
More news about: ADC Therapeutics SA
Jun 30, 2026, 01:36 ET EirGenix Showcases Dual-Track Biosimilars and CDMO Strategy in U.S. Market Push at BIO 2026
development efforts in next-generation ADC biosimilars.Beyond single-agent development, EirGenix is also exploring combination therapy strategies to address mechanisms of resistance in oncology treatment. These include potential co-development approaches involving ADC biosimilars alongside immune checkpoint
More news about: EirGenix
Jun 25, 2026, 14:15 ET Tigerlily Foundation Celebrates FDA Approval of Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer
status, or geography — has access to the latest evidence-based care."What Changed?Trodelvy is an antibody-drug conjugate, or ADC, a targeted cancer therapy designed to deliver chemotherapy directly to cancer cells expressing the Trop-2 protein while limiting exposure to healthy
More news about: TIGERLILY FOUNDATION
Jun 25, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
YORK, June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC" or the "Company") (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at
More news about: Pomerantz LLP
Jun 24, 2026, 07:30 ET ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities
therapy.About ADC Therapeutics ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA® (loncastuximab tesirine-lpyl).ADC Therapeutics'
More news about: ADC Therapeutics SA
Jun 22, 2026, 20:00 ET CPHI/ Hi Korea 2026 Opens Pre-Registration: Korea's Hub for Pharma, Biopharma, and Health Innovation
health functional food regulations.On the bio and pharma side, dedicated sessions spotlight Korea's emerging K-platform technologies, including ADC, TPD, and RPT, and clinical trials, alongside the latest GLP-1-related developments. The program also features the Biohealth Policy Forum hosted by KDRA,
More news about: Informa Markets Korea
Jun 22, 2026, 20:00 ET CPHI/ Hi Korea 2026 Opens Pre-Registration: Korea's Hub for Pharma, Biopharma, and Health Innovation
health functional food regulations.On the bio and pharma side, dedicated sessions spotlight Korea's emerging K-platform technologies, including ADC, TPD, and RPT, and clinical trials, alongside the latest GLP-1-related developments. The program also features the Biohealth Policy Forum
More news about: Informa Markets Korea
Jun 22, 2026, 15:07 ET SystImmune Announces First Approval of Iza-bren for the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma in China
Executive Officer of Biokin. "In fact, this is the first bispecific ADC approval of any kind globally. This approval validates our innovative EGFR×HER3 bispecific ADC design and the potential of our proprietary brengitecan-based ADC platform. Most importantly, it brings an important new treatment option
More news about: SystImmune, Inc.
Jun 22, 2026, 01:45 ET Translational Research Results of Sacituzumab Tirumotecan (sac-TMT) in Combination with Osimertinib as First-Line Treatment for EGFR-Mutant NSCLC Published in Cancer Cell
in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please
More news about: Kelun-Biotech
Jun 21, 2026, 20:30 ET Antengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE
preclinical to commercial stages, with key investigational candidates including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 x 4-1BB bispecific antibody), ATG-125 (B7-H3 × PD-L1 bispecific ADC), ATG-207 (αCD3-TGF-β bifunctional fusion protein), as well as T cell engager (TCE) programs
More news about: Antengene Corporation Limited
Jun 21, 2026, 20:00 ET Innovent Biologics Announces First Patient Dosed in a Phase 3 Clinical Trial of IBI3003(GPRC5D/BCMA/CD3 Tri-specific Antibody) for the Treatment of Multiple Myeloma
bring a promising next-generation immunotherapy option for patients with multiple myeloma. Looking ahead, Innovent will deepen its dual innovation in ADC and immunotherapy, and is committed to delivering cutting-edge therapies to patients worldwide."About Multiple MyelomaMultiple Myeloma
More news about: Innovent Biologics